References
- Gilead to Acquire Forty Seven for $4.9 Billion. www.gilead.com/news-and-press/press-room/press-releases/2020/3/gilead-to-acquire-forty-seven-for-49-billion
- Forty Seven . Science: why CD47 matters.www.fortyseveninc.com/science
- Chao MP , TakimotoCH , FengDD , McKennK , GipP , LiuJ , VolkmerJP , WeissmanIL , MajetR. Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies. Front. Oncol.9, 1380 (2020).
- Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines. www.sitryx.com/news-and-events/press-releases/2020/
- Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus. https://ir.moleculin.com/press-releases/detail/157/moleculin-signs-agreement-with-utmb-to-test-wp1122-on-a
- Moleculin Biotech: WP1122. www.moleculin.com/technology/wp1122/
- Silence Therapeutics Announces Collaboration with AstraZeneca to Discover and Develop siRNA Therapeutics for Cardiovascular, Renal, Metabolic and Respiratory Diseases. www.silence-therapeutics.com/media/2012/silence-collaboration-with-astrazeneca-250320-final.pdf
- Sanofi Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19. https://investors.translate.bio/news-releases/news-release-details/sanofi-pasteur-and-translate-bio-collaborate-develop-novel-mrna
- Forge Therapeutics. Antibiotic pipeline. https://forgetherapeutics.com/pipeline/
- Kalinin DV , HollR. LpxC inhibitors: a patent review (2010–2016). Expert Opin. Ther. Pat.27, 1227–1250 (2017).
- Galster M , LöppenbergM , GallaF , BörgelF , AgoglittaO , KirchmairJ , HollR. Phenylethylene glycol-derived LpxC inhibitors with diverse Zn2+-binding groups. Tetrahedron75, 486–509 (2019).
- Forge Enters into Collaboration with Roche to Develop Novel Antibiotic to Treat Lung Infections. https://forgetherapeutics.com/forge-enters-into-collaboration-with-roche-to-develop-novel-sntibiotic-to-treat-lung-infections/
- CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop Probody® T-Cell Engaging Bispecific Therapies for Treatment of Cancer. http://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-and-astellas-announce-strategic
- CytomX Therapeutics: how Probody therapeutics work. https://cytomx.com/probody-therapeutics/#how-probody-therapeutics-work
- EGFR-CD3 Bispecific Probody™ Therapeutic Induces Tumor Regressions and Increases Maximum Tolerated Dose >60 fold in Preclinical Studies. https://cytomx.com/wp-content/uploads/CytomX-PbTCB_AACR_NCI_EORTC_2017_FINAL.pdf
- Dragonfly Therapeutics: How our technology works. www.dragonflytx.com/copy-of-about-us-1
- Dragonfly Therapeutics Announces Multi-Target Expansion of its Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Therapeutic Candidates in the fields of Oncology, Infectious Disease, and Immune Disorders. www.prnewswire.com/news-releases/dragonfly-therapeutics-announces-multi-target-expansion-of-its-collaboration-with-merck-to-use-dragonflys-proprietary-trinket-platform-to-develop-novel-therapeutic-candidates-in-the-fields-of-oncology-infectious-disease-and-im-301026451.html
- Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine. https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-and-BioNTech-to-Co-Develop-Potential-COVID-19-Vaccine/default.aspx
- BioNTech: Science, Platforms . https://biontech.de/science/platforms
- BioNTech: How we translate, mRNA therapeutics . https://biontech.de/how-we-translate/mrna-therapeutics
- BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza. https://investors.biontech.de/news-releases/news-release-details/biontech-signs-collaboration-agreement-pfizer-develop-mrna-based
- Orionis Biosciences debuts with major pharmaceutical collaboration to tackle industry's most challenging protein targets. https://orionisbio.com/2020/03/orionis-debuts-major-pharmaceutical-collaboration/
- Allo-Glue™ platform https://orionisbio.com/platforms/
- Vir and Alnylam expand collaboration to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. https://investors.alnylam.com/press-release?id=24656
- Regeneron announces important advances in novel COVID-19 antibody program. https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody
- Regeneron and Sanofi begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19. https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-and-sanofi-begin-global-kevzarar-sarilumab-clinical
- Amarin comments on ruling in Vascepa® ANDA Litigation. https://investor.amarincorp.com/news-releases/news-release-details/amarin-comments-ruling-vascepar-anda-litigation
- GigaGen initiates development of recombinant polyclonal antibody therapy for COVID-19. www.globenewswire.com/news-release/2020/03/30/2008438/0/en/GigaGen-Initiates-Development-of-Recombinant-Polyclonal-Antibody-Therapy-for-COVID-19.html
- Johnson & Johnson announces a lead vaccine candidate for COVID-19; landmark new partnership with U.S. Department of Health & Human Services; and commitment to supply one billion vaccines worldwide for emergency pandemic use. www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use
- Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research discover novel class of candidate anti malaria agents that block multiple stages of the lifecycle of the parasite. www.mrknewsroom.com/news-release/research-and-development-news/scientists-merck-and-walter-and-eliza-hall-institute-medi
- Favuzza P , deLera Ruiz M , ThompsonJKet al. Dual plasmepsin-targeting antimalarial agents disrupt multiple stages of the malaria parasite life cycle. Cell Host Microbe 27, 642–658.
- Burrows JN , Soldati-FavreD. Targeting plasmepsins – an Achilles' heel of the malaria parasite. Cell Host Microbe27, 496–498.
- Intercept Pharmaceuticals Provides Regulatory and Business Update. http://ir.interceptpharma.com/news-releases/news-release-details/intercept-pharmaceuticals-provides-regulatory-and-business
- Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic. http://lilly.mediaroom.com/index.php?s=9042&item=138028
- bluebird bio provides assessment of impact of COVID-19, update on business operations and clinical program development. http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-provides-assessment-impact-covid-19-update-business
- Moderna Provides Update on the Impact of COVID-19 on Business Operations and Clinical Program Development. https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-update-impact-covid-19-business-operations-and
- Vertex Confirms Supply Chain Continuity and Business Outlook for Its Cystic Fibrosis Medicines and Provides Initial Update on Development Programs. www.businesswire.com/news/home/20200327005081/en/Vertex-Confirms-Supply-Chain-Continuity-Business-Outlook
- U.S. drugmaker Pfizer pauses new studies due to coronavirus pandemic. https://uk.reuters.com/article/us-health-coronavirus-pfizer/us-drugmaker-pfizer-pauses-new-studies-due-to-coronavirus-pandemic-idUKKBN21C2WD
- Bristol Myers Squibb: Investor Fact Sheet related to COVID-19. www.sec.gov/Archives/edgar/data/14272/000114036120006780/nc10009726x2_ex99-1.htm
- Bristol Myers Squibb and bluebird bio announce submission of biologics license application (BLA) for anti-BCMA CAR T cell therapy idecabtagene vicleucel (Ide-cel, bb2121) to FDA. https://news.bms.com/press-release/celltherapy/bristol-myers-squibb-and-bluebird-bio-announce-submission-biologics-licens
- AveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA). www.novartis.com/news/media-releases/avexis-receives-positive-chmp-opinion-zolgensma-only-gene-therapy-spinal-muscular-atrophy-sma
- Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA). www.novartis.com/news/media-releases/novartis-receives-approval-from-japanese-ministry-health-labour-and-welfare-zolgensma-only-gene-therapy-patients-spinal-muscular-atrophy-sma
- U.S. Food and Drug Administration approves Bristol Myers Squibb's Zeposia® (ozanimod), a new oral treatment for relapsing forms of multiple sclerosis. https://news.bms.com/press-release/corporatefinancial-news/us-food-and-drug-administration-approves-bristol-myers-squibbs
- Bristol Myers Squibb receives positive CHMP opinion recommending approval of Zeposia® (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease. https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-receives-positive-chmp-opinion-recommen-4
- CanSinoBIO's Investigational Vaccine Against COVID-19 Approved for Phase 1 Clinical Trial in China. www.cansinotech.com/homes/article/show/56/153.html
- Recordati announces US NDA approval of Isturisa® (osilodrostat), the first and only FDA approved cortisol synthesis inhibitor for patients with Cushing's disease. Company builds endocrinology business unit in the U.S. https://www.recordati.com/resources/Pubblicazione/___ff2237c80538469094fc53c1635acdaf_/isturisa-approval-in-us.pdf
- Allergan receives FDA approval for Durysta™ (bimatoprost implant) the first and only intracameral biodegradable sustained-release implant to lower intraocular pressure in open-angle glaucoma or ocular hypertension patients. www.allergan.com/News/Details/2020/03/Allergan%20Receives%20FDA%20Approval%20for%20DURYSTA%20bimatoprost%20implant%20the%20First%20and%20Only%20Intracameral%20Biode
- Lee SS , HughesP , RossAD , RobinsonMR. Biodegradable implants for sustained drug release in the eye. Pharm. Res.27, 2043–2053 (2010).
- Seal JR , RobinsonMR , BurkeJ , BejanianM , CooteM , AttaM. Intracameral sustained release bimatoprost implant delivers bimatoprost to target tissues with reduced exposure to off-target tissues. J. Ocul. Pharmacol. Ther.35, 50–57 (2019).
- Craven ER , WaltersT , ChristieWCet al. 24-month Phase I/II clinical trial of bimatoprost sustain-release implant (bimatoprost SR) in glaucoma patients. Drugs80, 167–179 (2020).
- Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes. http://lilly.mediaroom.com/index.php?s=9042&item=137973
- US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes. www.boehringer-ingelheim.us/press-release/us-fda-issues-complete-response-letter-empagliflozin-25-mg-adjunct-insulin-adults-type
- Imfinzi approved in the US for extensive-stage small cell lung cancer. www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/imfinzi-approved-in-the-us-for-extensive-stage-small-cell-lung-cancer.html
- Fujifilm announces the start of a phase III clinical trial of influenza antiviral drug “Avigan Tablet” on COVID-19 and commits to increasing production. www.fujifilm.com/jp/en/news/hq/3211?_ga=2.68623063.797484450.1587031482-448542360.1587031482
- Information of Avigan tablet in relation to Covid-19. http://fftc.fujifilm.co.jp/en/avigan/index.html
- All AKR-001 dose groups met week 12 efficacy endpoints in NASH Phase 2a BALANCED study. https://ir.akerotx.com/news-releases/news-release-details/all-akr-001-dose-groups-met-week-12-efficacy-endpoints-nash
- Akero Therapeutics: presentations. https://ir.akerotx.com/static-files/97f63a36-345d-485c-a024-7c030f853280
- Regeneron announces American College of Cardiology presentation of positive Phase 3 evinacumab results in patients with severe inherited form of high cholesterol. https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-american-college-cardiology-presentation
- New clinical study data for Gilead's investigational HIV-1 capsid inhibitor GS-6207 presented at CROI. (2020). www.gilead.com/news-and-press/press-room/press-releases/2020/3/new-clinical-study-data-for-gileads-investigational-hiv-1-capsid-inhibitor-gs-6207-presented-at-croi-2020
- Treatment with Gilead's vesatolimod is evaluated for safety and virologic and immunologic response versus placebo in Phase 1b HIV functional cure study. www.gilead.com/news-and-press/press-room/press-releases/2020/3/treatment-with-gileads-vesatolimod-is-evaluated-for-safety-and-virologic-and-immunologic-response-versus-placebo-in-phase-1b-hiv-functional-cure-stud
- Janssen announces results of Phase 3 study demonstrating the safety and efficacy of long-acting injectable HIV treatment regimen of rilpivirine and cabotegravir through 96 weeks. www.jnj.com/janssen-announces-results-of-phase-3-study-demonstrating-the-safety-and-efficacy-of-long-acting-injectable-hiv-treatment-regimen-of-rilpivirine-and-cabotegravir-through-96-weeks
- Janssen announces 48-week results of Phase 3b study demonstrating the safety and efficacy of long-acting injectable HIV treatment of rilpivirine and cabotegravir administered every two months. www.jnj.com/janssen-announces-48-week-results-of-phase-3b-study-demonstrating-the-safety-and-efficacy-of-long-acting-injectable-hiv-treatment-of-rilpivirine-and-cabotegravir-administered-every-two-months
- Merck announces top-line results from Phase 3 trials evaluating gefapixant, an investigational treatment for refractory or unexplained chronic cough. www.mrknewsroom.com/news-release/prescription-medicine-news/merck-announces-top-line-results-phase-3-trials-evaluating-g
- Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing. www.novartis.com/news/media-releases/zolgensma-data-shows-rapid-significant-clinically-meaningful-benefit-sma-including-prolonged-event-free-survival-motor-milestone-achievement-and-durability-now
- AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2. www.novartis.com/news/media-releases/avexis-presents-avxs-101-it-data-demonstrating-remarkable-increases-hfmse-scores-and-consistent-clinically-meaningful-response-older-patients-sma-type-2
- Investigational drug vericiguat significantly reduced the risk of the composite endpoint of heart failure hospitalization or cardiovascular death, compared to placebo, when given in combination with available heart failure therapies. www.mrknewsroom.com/news-release/research-and-development-news/investigational-drug-vericiguat-significantly-reduced-ris
- Esperion announces three data presentations of the Nexletol™ (bempedoic acid) tablet and the Nexlizet™ (bempedoic acid and ezetimibe) tablet at the American College of Cardiology's 69th Annual Scientific Session together with world congress of cardiology. https://esperion.gcs-web.com/node/11361/pdf
- Farxiga reduced the incidence of heart failure worsening or cardiovascular death in a sub-analysis from landmark Phase III DAPA-HF trial. www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/farxiga-reduced-the-incidence-of-heart-failure-worsening-or-cardiovascular-death-in-a-sub-analysis-from-landmark-phase-iii-dapa-hf-trial.html
- Blueprint medicines announces part 1 results from pioneer trial showing broad activity of avapritinib across measures of mast cell burden, clinical outcomes and quality of life in indolent systemic mastocytosis. http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-part-1-results-pioneer-trial
- Moderna announces first participant dosed in NIH-led Phase 1 study of mRNA vaccine (mRNA-1273) against novel coronavirus. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participant-dosed-nih-led-phase-1-study